Overview

Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

Status:
Withdrawn

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

This randomized trial is being conducted to show non-inferiority of OctaAlpha1 compared to Glassia® in terms of the serum trough levels at steady state. This will be conducted in individuals with alpha-1-antitrypsin deficiency and clinical evidence of emphysema.

Phase:

Phase 2

Details

Lead Sponsor:

Octapharma

Treatments:

Alpha 1-Antitrypsin